>
Switch to:

Travere Therapeutics EV-to-EBITDA

: -20.87 (As of Today)
View and export this data going back to 2003. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Travere Therapeutics's enterprise value is $1,143.5 Mil. Travere Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was $-54.8 Mil. Therefore, Travere Therapeutics's EV-to-EBITDA for today is -20.87.

NAS:TVTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.2   Med: -9.9   Max: 144.8
Current: -20.87

-47.2
144.8

During the past 9 years, the highest EV-to-EBITDA of Travere Therapeutics was 144.80. The lowest was -47.20. And the median was -9.90.

NAS:TVTX's EV-to-EBITDA is ranked lower than
99.99% of the 273 Companies
in the Biotechnology industry.

( Industry Median: 32.12 vs. NAS:TVTX: -20.87 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-01-26), Travere Therapeutics's stock price is $27.170000. Travere Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-1.70. Therefore, Travere Therapeutics's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Travere Therapeutics EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Travere Therapeutics Annual Data
Feb11 Feb12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 -13.79 -15.11 -9.29 -3.90

Travere Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.47 -3.90 -5.72 -11.22 -12.71

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Travere Therapeutics EV-to-EBITDA Distribution

* The bar in red indicates where Travere Therapeutics's EV-to-EBITDA falls into.



Travere Therapeutics EV-to-EBITDA Calculation

Travere Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1143.462/-54.802
=-20.87

Travere Therapeutics's current Enterprise Value is $1,143.5 Mil.
Travere Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2020 was -20.339 (Dec. 2019 ) + -7.625 (Mar. 2020 ) + -15.518 (Jun. 2020 ) + -11.32 (Sep. 2020 ) = $-54.8 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Travere Therapeutics  (NAS:TVTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Travere Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27.170000/-1.7
=

Travere Therapeutics's share price for today is $27.170000.
Travere Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was -0.7 (Dec. 2019 ) + 0.02 (Mar. 2020 ) + -0.58 (Jun. 2020 ) + -0.44 (Sep. 2020 ) = $-1.70.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Travere Therapeutics EV-to-EBITDA Related Terms


Travere Therapeutics EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)